You are currently browsing the archives for 23 December 2016.
Displaying 1 entry.

Dose escalation continued the primary endpoints of the study.

Results from an ongoing Phase 1 trial in patients with refractory solid tumors demonstrated that ENMD-2076 28-day 28-day cycles was well tolerated. The data show the first evidence of anti-tumor activity reduction in tumor reduction in tumor markers in ovarian and colorectal cancer patients. Dose escalation continued the primary endpoints of the study, safety, pharmacokinetics and a Phase 2 to determine dose.

Low birth weight may be due to malnutrition due to parent homelessness, hunger and their desire not caused to gain too much weight during pregnancy. Other causes are diseases or infections, a reduction in placental blood flow, smoking or use of alcohol or drugs during pregnancy.